Approval for nuflexxa (1% sodium hyaluronate).  The device is indicated for the treatment of pain in osteoarthritis (oa) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e. g., acetaminophen).